SUPPLEMENTAL FINANCIAL INFORMATION
STOCK-BASED COMPENSATION EXPENSE (Unaudited, in thousands) | ||||||||
Three Months Ended March 31, | ||||||||
2021 | 2020 | |||||||
Cost of revenue | $ | 816 | $ | 557 | ||||
Research and development | 6,165 | 4,370 | ||||||
Selling, general and administrative | 21,602 | 13,635 | ||||||
Total stock-based compensation expense | $ | 28,583 | $ | 18,562 | ||||
RECONCILIATION OF NET INCOME TO NON-GAAP NET INCOME
(Unaudited, in thousands, except per share amounts) | ||||||||
Three Months Ended March 31, | ||||||||
2021 | 2020 | |||||||
Net income | $ | 45,413 | $ | 35,756 | ||||
Adjustments to reconcile net income to non-GAAP net income: | ||||||||
Stock-based compensation expense | 28,583 | 18,562 | ||||||
Deferred compensation plan expense (income) | (57 | ) | 94 | |||||
Tax effect | (4,460 | ) | (10,079 | ) | ||||
Non-GAAP net income | $ | 69,479 | $ | 44,333 | ||||
Non-GAAP net income per share: | ||||||||
Basic | $ | 1.53 | $ | 1.00 | ||||
Diluted | $ | 1.46 | $ | 0.95 | ||||
Shares used in the calculation of non-GAAP net income per share: | ||||||||
Basic | 45,498 | 44,455 | ||||||
Diluted | 47,711 | 46,670 |